CytRx announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin, formerly known as INNO-206, primarily in patients with advanced soft tissue sarcoma will be featured in a poster presentation at the ESMO 2012 Congress being held September 28 - October 2 in Vienna, Austria.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?